Haleon PLC

HLN

Company Profile

  • Business description

    Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

  • Contact

    The Heights
    Building 5, First Floor
    Surrey
    WeybridgeKT13 0NY
    GBR

    T: +44 1932959500

    E: [email protected]

    https://www.haleon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    24,622

Stocks News & Analysis

stocks

Expense concerns for ASX best idea

Expense guidance changes short-term earnings but not long-term fundamentals.
stocks

Chart of the Week: Australian asset managers face structural pressure

Read the latest take from our analysts.
stocks

Going into earnings, is Alphabet a buy, a sell, or fairly valued?

From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,204.3039.00-0.42%
CAC 408,066.6886.14-1.06%
DAX 4024,822.7971.65-0.29%
Dow JONES (US)49,015.6012.190.02%
FTSE 10010,154.4353.37-0.52%
HKSE27,975.81148.900.54%
NASDAQ23,857.4540.350.17%
Nikkei 22553,455.0796.360.18%
NZX 50 Index13,348.6164.26-0.48%
S&P 5006,978.030.57-0.01%
S&P/ASX 2008,897.8025.40-0.28%
SSE Composite Index4,147.154.08-0.10%

Market Movers